Peripheral blood leukocyte NO production in MS patients with a benign vs progressive course

Neurology

Volumn 62, Issue 2, 2004, Pages 239-242

  Ramsaransing, Geeta S M ^a   Teelken, Albert ^a   Arutjunyan, Alexander V ^b   De Keyser, Jacques ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b D O OTT RESEARCH INSTITUTE OF OBSTETRICS   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; NITRIC OXIDE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; PRIORITY JOURNAL; TISSUE INJURY;

EID: 0842325648     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000103239.72937.AD     Document Type: Article

References (37)

1. Parkinson JF, Mitrovic B, Merrill JE. The role of nitric oxide in multiple sclerosis. J Mol Med 1997;75:174-186.
2. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002;1:232-241.
3. Bo L, Dawson TM, Wesselingh S, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994;36:778-786.
4. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, Van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997;56:10-20.
5. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001;158:2057-2066.
6. Acar G, Idiman F, Idiman E, Kirkali G, Cakmakci H, Ozakbas S. Nitric oxide as an activity marker in multiple sclerosis. J Neurol 2003;250:588-592.
7. Danilov AI, Andersson M, Bavand N, Wiklund NP, Olsson T, Brundin L. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol 2003;136:112-118.
8. Svenningsson A, Petersson AS, Andersen O, Hansson GK. Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. Neurology 1999;53:1880-1882.
9. Yamashita T, Ando Y, Obayashi K, Uchino M, Ando M. Changes in nitrite and nitrate (NO2-/NO3-) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 1997;153:32-34.
10. Brundin L, Morcos E, Olsson T, Wiklund NP, Andersson M. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol 1999;6:585-590.
11. Giovannoni G. Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult Scler 1998;4:27-30.
12. Giovannoni G, Heales SJ, Silver NC, et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci 1997;145:77-81.
13. Nazliel B, Taskiran D, Irkec C, Kutay FZ, Pogun S. Serum nitric oxide metabolites in patients with multiple sclerosis. J Clin Neurosci 2002;9:530-532.
14. Yuceyar N, Taskiran D, Sagduyu A. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Clin Neurol Neurosurg 2001;103:206-211.
15. Sarchielli P, Orlacchio A, Vicinanza F, et al. Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. J Neuroimmunol 1997;80:76-86.
16. Beenakker EA, Oparina TI, Hartgring A, Teelken A, Arutjunyan AV, De Keyser J. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology 2001;57:892-894.
17. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893-901.
18. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121(Pt 8):1469-1477.
19. Goode HF, Webster NR, Howdle PD, Walker BE. Nitric oxide production by human peripheral blood polymorphonuclear leucocytes. Clin Sci (Lond) 1994;86:411-415.
20. Pahan K, Sheikh FG, Liu X, Hilger S, McKinney M, Petro TM. Induction of nitric-oxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells. J Biol Chem 2001;276:7899-7905.
21. Salvucci O, Kolb JP, Dugas B, Dugas N, Chouaib S. The induction of nitric oxide by interleukin-12 and tumor necrosis factor-alpha in human natural killer cells: relationship with the regulation of lytic activity. Blood 1998;92:2093-2102.
22. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148-152.
23. Percy AK, Brady RO. Metachromatic leukodystrophy: diagnosis with samples of venous blood. Science 1968;161:594-595.
24. Lowry OH, Rosenbrough NJ, Farr A, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
25. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138.
26. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199-1204.
27. De Servi B, La Porta CA, Bontempelli M, Comolli R. Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. Exp Gerontol 2002;37:813-821.
28. Mitsuke Y, Lee JD, Shimizu H, Uzui H, Iwasaki H, Ueda T. Nitric oxide synthase activity in peripheral polymorphonuclear leukocytes in patients with chronic congestive heart failure. Am J Cardiol 2001;87:183-187.
29. Pascualy M, Petrie EC, Brodkin K, Peskind ER, Wilkinson CW, Raskind MA. Hypothalamic pituitary adrenocortical and sympathetic nervous system responses to the cold pressor test in Alzheimer's disease. Biol Psychiatry 2000;48:247-254.
30. Cosentino M, Zaffaroni M, Marino F, et al. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J Neuroimmunol 2002;133:233-240.
31. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997;120(Pt 12):2149-2157.
32. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999;9:69-92.
33. Davie CA, Silver NC, Barker GJ, et al. Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry 1999;67:710-715.
34. Taylor-Robinson AW, Liew FY, Severn A, et al. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol 1994;24:980-984.
35. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-68.
36. O'Brien NC, Charlton B, Cowden WB, Willenborg DO. Nitric oxide plays a critical role in the recovery of Lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction. J Immunol 1999;163:6841-6847.
37. Kahl KG, Zielasek J, Uttenthal LO, Rodrigo J, Toyka KV, Schmidt HH. Protective role of the cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat. J Neurosci Res 2003;73:198-205.